Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Taiwan · Delayed Price · Currency is TWD

80.20

-0.70 (-0.87%)

Sep 24, 2026, 1:30 PM CST

Market Cap	12.63B -2.8%
Revenue (ttm)	471.13M +6.4%
Net Income	22.50M
EPS	0.14
Shares Out	157.54M
PE Ratio	561.64
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,560
Open	80.20
Previous Close	80.90
Day's Range	80.10 - 80.50
52-Week Range	71.90 - 93.70
Beta	0.58
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2013

Employees 15

Stock Exchange Taipei Exchange

Ticker Symbol 6576

Full Company Profile

Financial Performance

In 2025, Foresee Pharmaceuticals's revenue was 431.27 million, an increase of 3.01% compared to the previous year's 418.69 million. Losses were -883.15 million, -18.31% less than in 2024.

Financial Statements